Details of the Drug

General Information of Drug (ID: DM0Q8MZ)

• Drug Name: Trimethadione
• Synonyms: Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Approved	[1], [2], [3]
Pancreatic cancer	2C10	Approved	[1], [2], [3]

• Therapeutic Class: Anticonvulsants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 143.14
  Topological Polar Surface Area (xlogp); 0.3
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property: MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 279.43982 micromolar/kg/day [4]
• Chemical Identifiers:
  Formula: C6H9NO3
  IUPAC Name: 3,5,5-trimethyl-1,3-oxazolidine-2,4-dione
  Canonical SMILES: CC1(C(=O)N(C(=O)O1)C)C
  InChI: InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
  InChIKey: IRYJRGCIQBGHIV-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5576
  ChEBI ID: CHEBI:9727
  CAS Number: 127-48-0
  DrugBank ID: DB00347
  TTD ID: D0U4VT
  INTEDE ID: DR1647
  ACDINA ID: D00705

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	TT729IR	CAC1G_HUMAN	Blocker	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[6]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[6]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Trimethadione (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Trimethadione when combined with Levomilnacipran.	Chronic pain [MG30]	[57]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Trimethadione and Olopatadine.	Conjunctiva disorder [9A60]	[58]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Trimethadione and Ethanol.	Cystitis [GC00]	[58]
Sertraline	DM0FB1J	Moderate	Antagonize the effect of Trimethadione when combined with Sertraline.	Depression [6A70-6A7Z]	[57]
Fluoxetine	DM3PD2C	Moderate	Antagonize the effect of Trimethadione when combined with Fluoxetine.	Depression [6A70-6A7Z]	[57]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Trimethadione when combined with Vilazodone.	Depression [6A70-6A7Z]	[57]
Paroxetine	DM5PVQE	Moderate	Antagonize the effect of Trimethadione when combined with Paroxetine.	Depression [6A70-6A7Z]	[57]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Trimethadione when combined with Vortioxetine.	Depression [6A70-6A7Z]	[57]
Duloxetine	DM9BI7M	Moderate	Antagonize the effect of Trimethadione when combined with Duloxetine.	Depression [6A70-6A7Z]	[57]
Milnacipran	DMBFE74	Moderate	Antagonize the effect of Trimethadione when combined with Milnacipran.	Depression [6A70-6A7Z]	[57]
Escitalopram	DMFK9HG	Moderate	Antagonize the effect of Trimethadione when combined with Escitalopram.	Depression [6A70-6A7Z]	[57]
Desvenlafaxine	DMHD4PE	Moderate	Antagonize the effect of Trimethadione when combined with Desvenlafaxine.	Depression [6A70-6A7Z]	[57]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Trimethadione and Esketamine.	Depression [6A70-6A7Z]	[59]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Trimethadione and Brimonidine.	Glaucoma [9C61]	[60]
Chloroquine	DMSI5CB	Moderate	Antagonize the effect of Trimethadione when combined with Chloroquine.	Malaria [1F40-1F45]	[59]
Hydroxychloroquine	DMSIVND	Moderate	Antagonize the effect of Trimethadione when combined with Hydroxychloroquine.	Malaria [1F40-1F45]	[59]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Trimethadione and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[61]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Trimethadione and Lasmiditan.	Migraine [8A80]	[62]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Trimethadione and Flibanserin.	Mood disorder [6A60-6E23]	[63]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Trimethadione and Thalidomide.	Multiple myeloma [2A83]	[58]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Trimethadione and Ocrelizumab.	Multiple sclerosis [8A40]	[64]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Trimethadione and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[65]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Trimethadione and Apraclonidine.	Optic nerve disorder [9C40]	[60]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Trimethadione and Dextropropoxyphene.	Pain [MG30-MG3Z]	[66]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Trimethadione and Buprenorphine.	Pain [MG30-MG3Z]	[67]
Meperidine	DMX4GND	Moderate	Additive CNS depression effects by the combination of Trimethadione and Meperidine.	Pain [MG30-MG3Z]	[68]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Trimethadione and Tizanidine.	Tonus and reflex abnormality [MB47]	[69]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Trimethadione and Ganciclovir.	Virus infection [1A24-1D9Z]	[59]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Trimethadione and Valganciclovir.	Virus infection [1A24-1D9Z]	[59]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Magnesium trisilicate	E00477	5311266	Glidant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Trimethadione 150 mg tablet	150 mg	Chewable Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7316).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 005856.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
• [6] Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
• [7] Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002 Apr;66(2):185-200.
• [8] Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
• [9] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [10] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [11] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [12] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [15] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [16] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [17] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [18] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [19] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [20] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [21] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [22] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [23] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [24] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [25] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [26] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [27] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [28] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [29] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [30] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [31] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [32] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [33] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [34] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [35] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [36] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [37] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [38] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [39] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [40] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [41] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [42] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [43] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [44] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [45] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [46] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [47] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [48] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [49] Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
• [50] Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
• [51] Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
• [52] Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
• [53] Pfizer. Product Development Pipeline. March 31 2009.
• [54] The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
• [55] Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
• [56] Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
• [57] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
• [58] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [59] Cerner Multum, Inc. "Australian Product Information.".
• [60] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [61] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [62] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [63] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [64] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [65] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [66] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [67] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [68] Lambertsen CJ, Wendel H, Longenhagen JB "The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2." J Pharmacol Exp Ther 131 (1961): 381-93. [PMID: 13758472]
• [69] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.